ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
ExcelFemale
HRT in Women
Giving HIV+ women estrogen reduces the amount of HIV hidden in different reservoirs
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 158030" data-attributes="member: 3"><p>I wonder if the same can be said for men. Estradiol, the main estrogen in men, comes from the aromatization of testosterone. Men with low testosterone usually have low estradiol. They should study what happens to HIV reservoirs in HIV+ men with low testosterone who start testosterone replacement therapy.</p><p></p><p></p><p><a href="http://www.natap.org" target="_blank">www.natap.org</a></p><p></p><p>Hormonal control of HIV-1 latency by estrogen imparts gender-specific restrictions on the latent reservoir</p><p></p><p> "Consistent with these results, women who are undergoing menopause show</p><p></p><p>progressive increases in their RNA-inducible reservoir sizes.”</p><p></p><p>"Concurrent exposure to estrogen is likely to limit the efficacy of viral</p><p>emergence from latency and it is striking that reservoir sizes in women are</p><p>smaller than in men. Progression through stages of reproductive aging,</p><p>when estrogen levels fall, is predictive of expansion of the inducible RNA</p><p>reservoir. Finally, our studies suggest that high dose estrogen contraception</p><p>might have an impact on HIV acquisition and suppression of the viral</p><p>reservoir."</p><p>IAS 2019</p><p></p><p>Reported by Jules Levin </p><p></p><p>Curtis Dobrowolski1, Saba Valadkhan1, Monica Gandhi2, Steven G. Deeks2, Eileen Scully3, Kathleen M. Weber4, Alan L. Landay5, & Jonathan Karn1 </p><p></p><p>1 Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine. Cleveland, OH, USA2 University of California San Francisco, Division of HIV, Infectious Diseases and Global Medicine, Department of Medicine, San Francisco, CA, USA3 Johns Hopkins University, Department of Medicine, Division of Infectious Diseases, Baltimore, MD, USA4 WIHS/CORE Center of Cook County Health, Chicago, IL, USA 5 Rush University Medical Center, Department Internal Medicine, Chicago, IL, USA</p><p></p><p></p><p></p><p>program abstract</p><p></p><p>Background: Unbiased shRNA library screens revealed that the estrogen receptor-α (ESR-1) is a key factor regulating HIV-1 latency. HIV emergence from the latent reservoir can be manipulated with native ligands, agonists, and antagonists to ESR-1.</p><p>Methods: Hormone receptor manipulation by shRNA, CRISPR-mediate gene editing and inhibitory compounds was studied in primary cell models (QUECEL, Th17) infected ex vivo. Leukapheresis samples from a cohort of 12 well-matched reproductive age women and men on fully suppressive ART were evaluated by a novel assay measuring production of spliced envelope (env) mRNA (the EDITS assay). Additionally, longitudinal samples from women progressing through menopause have been evaluated.</p><p>Results: Although both sexes responded to β-estradiol and selective estrogen receptor modulators (SERMs), females showed much higher levels of inhibition in response to the hormone and higher reactivity in response to SERMs than males. Importantly, the total inducible RNA reservoir, as measured by EDITS, was significantly smaller in the women than in the men. Remarkably, estrogen nearly completely blocked viral spread in females before and after menopause, but not in males. Agonists and antagonists to other hormone receptors, including thyroid receptors (TR), androgen receptor (AR), and the glucocorticoid receptor (GR), can modulate HIV expression but are much less potent than drugs targeting ESR-1.</p><p>Conclusions: We conclude that concurrent exposure to estrogen is likely to limit the efficacy of viral emergence from latency and that ESR-1 is a pharmacologically attractive target that can be exploited in the design of therapeutic strategies for latency reversal. A preliminary trial of the effects of Tamoxifen and vorinostat on the HIV reservoir among postmenopausal HIV-infected women has completed enrollment (ACTG A5366, ClinicalTrials.gov Identifier: NCT03382834). Our studies also suggest that high dose estrogen contraception might have an impact on HIV acquisition and suppression of the viral reservoir and that estrogen treatment in transgender people might reduce viral reservoirs.</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 158030, member: 3"] I wonder if the same can be said for men. Estradiol, the main estrogen in men, comes from the aromatization of testosterone. Men with low testosterone usually have low estradiol. They should study what happens to HIV reservoirs in HIV+ men with low testosterone who start testosterone replacement therapy. [URL="http://www.natap.org"]www.natap.org[/URL] Hormonal control of HIV-1 latency by estrogen imparts gender-specific restrictions on the latent reservoir "Consistent with these results, women who are undergoing menopause show progressive increases in their RNA-inducible reservoir sizes.” "Concurrent exposure to estrogen is likely to limit the efficacy of viral emergence from latency and it is striking that reservoir sizes in women are smaller than in men. Progression through stages of reproductive aging, when estrogen levels fall, is predictive of expansion of the inducible RNA reservoir. Finally, our studies suggest that high dose estrogen contraception might have an impact on HIV acquisition and suppression of the viral reservoir." IAS 2019 Reported by Jules Levin Curtis Dobrowolski1, Saba Valadkhan1, Monica Gandhi2, Steven G. Deeks2, Eileen Scully3, Kathleen M. Weber4, Alan L. Landay5, & Jonathan Karn1 1 Department of Molecular Biology and Microbiology, Case Western Reserve University School of Medicine. Cleveland, OH, USA2 University of California San Francisco, Division of HIV, Infectious Diseases and Global Medicine, Department of Medicine, San Francisco, CA, USA3 Johns Hopkins University, Department of Medicine, Division of Infectious Diseases, Baltimore, MD, USA4 WIHS/CORE Center of Cook County Health, Chicago, IL, USA 5 Rush University Medical Center, Department Internal Medicine, Chicago, IL, USA program abstract Background: Unbiased shRNA library screens revealed that the estrogen receptor-α (ESR-1) is a key factor regulating HIV-1 latency. HIV emergence from the latent reservoir can be manipulated with native ligands, agonists, and antagonists to ESR-1. Methods: Hormone receptor manipulation by shRNA, CRISPR-mediate gene editing and inhibitory compounds was studied in primary cell models (QUECEL, Th17) infected ex vivo. Leukapheresis samples from a cohort of 12 well-matched reproductive age women and men on fully suppressive ART were evaluated by a novel assay measuring production of spliced envelope (env) mRNA (the EDITS assay). Additionally, longitudinal samples from women progressing through menopause have been evaluated. Results: Although both sexes responded to β-estradiol and selective estrogen receptor modulators (SERMs), females showed much higher levels of inhibition in response to the hormone and higher reactivity in response to SERMs than males. Importantly, the total inducible RNA reservoir, as measured by EDITS, was significantly smaller in the women than in the men. Remarkably, estrogen nearly completely blocked viral spread in females before and after menopause, but not in males. Agonists and antagonists to other hormone receptors, including thyroid receptors (TR), androgen receptor (AR), and the glucocorticoid receptor (GR), can modulate HIV expression but are much less potent than drugs targeting ESR-1. Conclusions: We conclude that concurrent exposure to estrogen is likely to limit the efficacy of viral emergence from latency and that ESR-1 is a pharmacologically attractive target that can be exploited in the design of therapeutic strategies for latency reversal. A preliminary trial of the effects of Tamoxifen and vorinostat on the HIV reservoir among postmenopausal HIV-infected women has completed enrollment (ACTG A5366, ClinicalTrials.gov Identifier: NCT03382834). Our studies also suggest that high dose estrogen contraception might have an impact on HIV acquisition and suppression of the viral reservoir and that estrogen treatment in transgender people might reduce viral reservoirs. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
ExcelFemale
HRT in Women
Giving HIV+ women estrogen reduces the amount of HIV hidden in different reservoirs
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top